By Cecilia Butini

GlaxoSmithKline PLC and Novavax Inc. said Monday that the two companies have reached an agreement in principle with the U.K. government to support the manufacturing of Novavax's coronavirus vaccine in the U.K.

Glaxo, a British pharmaceutical company, said it will provide fill-and-finish manufacturing capacity at its Barnard Castle facility in England starting in May 2021. Fill and finish is understood as the final stage of vaccine manufacturing, where vials are prepared and packaged for distribution.

A "rapid" technology transfer between Glaxo and U.S. pharmaceutical giant Novavax will begin immediately, the companies said.

The U.K. government has secured 60 million vaccine doses under an advance-purchase agreement with Novavax.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

March 29, 2021 13:08 ET (17:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more GSK Charts.